Lingyi Bio's AAV Gene Therapy LY-M001 for Gaucher Disease Receives IND Clearance in China Following FDA Orphan Drug Designation

Recently, according to the announcement on the CDE official website, the new drug clinical application for LY-M001, an AAV therapy for treating Gaucher's disease developed by Lingyi Biotech Co., Ltd., has been accepted by the NMPA. Notably, this product was granted orphan drug designation by the FDA just 10 days ago.

As for the development of Gaucher's disease drugs, Lingyi Biotech is clearly not an isolated case. These companies often adopt a multi-region and multi-report strategy, which is not surprising. Gaucher's disease is mainly classified into Type I, Type II, and Type III based on symptoms, along with some rare subtypes defined by bleeding and other symptoms, each affecting different patient populations.

Generally speaking, non-neuropathic (Type I) Gaucher's disease is the most common and least severe form of the condition, which can occur anywhere. Acute neuropathic (Type II) Gaucher's disease is more prevalent among Ashkenazi Jews (also known as Eastern European Jews, mainly distributed in Eastern and Central Europe, and the United States). Chronic neuropathic (Type III) Gaucher's disease has a higher incidence rate among Asians.

And with the gradual rise of various Biotech companies in recent years, even rare diseases like Gaucher's disease, which have very small patient populations (in China, it seems there are fewer than 3,000 patients, though estimates vary, with some suggesting the number hasn't exceeded a thousand), now have several pipeline candidates in development.

In addition to Lingyi Biotech and Sanofi, the dominant player in Gaucher's disease treatment mentioned earlier, several other companies have also begun clinical trials for Gaucher's disease.

For example, CAN103, an enzyme replacement therapy developed by the well-known Chinese rare disease company Canbridge Medical, which has entered Phase II clinical trials, targets Gaucher disease Type I and Type III.

VGN-R08b, an AAV gene therapy for the treatment of Type II Gaucher disease developed by Tianze Cloud-Tech, has now entered Phase II clinical trials.

Freeline Therapeutics may be the most prominent one recently. Despite tight cash flow, the company prioritized the AAV therapy FLT201 for treating Type I Gaucher disease and attracted buyers with clinical data from just two patients.

Avrobio's AAV gene therapy AVR-RD-02 has also demonstrated relatively excellent data in Type III Gaucher disease.